Most complete. Least manipulated. Good as Nu

When you're looking for convenience without compromise, give your patients NuShield®

the most complete, least manipulated dehydrated placental allograft wound covering available.

Not all placental allografts are created equal

While there are a variety of placental allografts on the market, the preservation methods vary. Some manufacturers remove part of the placental membrane, including the amnion, chorion, epithelium, or spongy layer.1

The more an allograft is manipulated, including the removal of layers, the more limited the growth factor content—and, therefore, the more limited the potential for regenerative healing.1-6

The unique preservation method retains all native layers

  • By preserving the amnion layer, NuShield retains an abundant source of growth factors/cytokines and ECM8
  • Including the chorion layer in NuShield also results in a thicker graft, which may improve handling characteristics11
ECM=extracellular matrix

The Nu Results

Proven growth factor release

In vitro studies have shown that NuShield:

  • Contains 640 proteins

    Including growth factors, cytokines, and chemokines10

  • Supports wound healing

    Releases growth factors and cytokines over a 7-day period that are important to the wound healing process3,8

  • Stimulates cell proliferation

    Increases fibroblast and keratinocyte proliferation8

Note: NuShield is intended for use as a wound covering.

NuShield provides 42% higher concentrations of growth factors and cytokines11

Note: * indicates significance where P<0.05; ◊ indicates significance where P<0.01.

A broad evaluation of proteins found that NuShield, compared to another commercially available dHACM, provided statistically significant higher concentrations of many growth factors and cytokines.11

NuShield provides, on average, over 6x more hyaluronic acid11

Note: * indicates significance where P<0.05

HA holds vast amounts of moisture, serves as filling material for ECM, and acts as an adhesive substrate for cellular migration.12

In this evaluation, HA levels were significantly higher in NuShield than in another commercially available dHACM, with an average of 3.25 µg/cm2 HA in NuShield compared to 0.52 µg/cm2 HA in the other commercially available dHACM.11

dHACM=dehydrated human amnion/chorion membrane; HA=hyaluronic acid

Median time to wound closure

In real-world patients (retrospective case series), NuShield was used in a wide variety of wounds (N=50), including VLUs (n=14), DFUs (n=24), and other wounds (pressure ulcers, nonhealing surgical, ischemic, mixed etiology, and nonhealing amputation; n=12).13

Estimated median time to complete wound closure for wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata: P=0.071 (Wilcoxon). All wounds includes DFUs, VLUs, and other wounds. Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wounds; 1 nonhealing amputation; and 1 not identified.
VLU=venous leg ulcer; DFU=diabetic foot ulcer

Percentage of wounds closed by week

In real-world patients (retrospective case series), NuShield was used in a wide variety of wounds (N=50), including VLUs (n=14), DFUs (n=24), and other wounds (pressure ulcers, nonhealing surgical, ischemic, mixed etiology, and nonhealing amputation; n=12).13

Estimated frequency of complete wound closure for all wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata: P=0.071 (Wilcoxon). All wounds includes DFUs, VLUs, and other wounds. Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wounds; 1 nonhealing amputation; and 1 not identified.

Of those wounds that did not achieve wound closure, 9 (18%) had >90% wound closure, and 8 (16%) had wound closures ranging from 60% to 90% by the last observation.13

VLU=venous leg ulcer; DFU=diabetic foot ulcer

The Nu Versatility

Support healing from head to toe

  • As a dehydrated placental allograft wound covering with a 5-year shelf life, NuShield streamlines logistics and saves preparation time for busy clinical practices
  • Available in a wide range of shapes and sizes, allowing for flexibility when fitting a wound
  • Can be used for various wound types from head to toe, including those with exposed bone and tendon9

Not all placental allografts are good as Nu.

Talk to an Organogenesis Tissue Regeneration Specialist about the most complete dehydrated placental allograft today.

I am a:

Organogenesis will not sell, rent, or otherwise distribute your name or any personally identifiable information outside of Organogenesis and its agents. Organogenesis will only use your information in accordance with our Privacy Policy.

Thank you. We are processing your request... We are unable to process your request at this time. Please try again later.

Thank you.

We have received your information and will contact you shortly.

Solutions and support

Product portfolio

Our advanced wound care solutions empower patients and providers throughout the healing process.

See all products

Circle of Care

Our comprehensive program provides the highest-quality customer service and reimbursement support.

See program details

References:1. Koob TJ, et al. J Biomed Mater Res B Appl Biomater. 2014;102(6):1353-1362. 2. Niknejad H, et al. Eur Cells Mater. 2008;15:88-99. 3. McQuilling JP, et al. Wounds. 2017;29(6):E38-E42. 4. McQuilling JP, et al. Int Wound J. 2017;14(6):993-1005. 5. Abshier S. Podiatry Today. 2015;28(11):20-26. 6. Brantley JN, et al. Adv Wound Care. 2015;4(9):545-559. 7. Data on file. Description of BioLoc process. Organogenesis Inc. 8. McQuilling JP, et al. Int Wound J. 2019;16(3):827-840. 9. NuShield Allograft Tissue Information and Instructions for Use. Canton, MA: Organogenesis Inc; 2019. 10. McQuilling JP, et al. Wound Repair Regen. 2019;27(6):609-621. 11. Data on file. DR-0004. Organogenesis Inc. 12. Litwiniuk M, et al. Wounds. 2016;28(3):78-88. 13. Caporusso J, et al. Wounds. 2019;31(4 suppl):S19-S27.